Raber-Durlacher, Judith E.
Zadik, Yehuda
Treister, Nathaniel S.
Stempler, Noa
Bruno, Julia S.
Epstein, Joel B.
Elad, Sharon
Article History
Received: 7 June 2024
Accepted: 24 June 2024
First Online: 25 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: N. S. Treister, N. Stempler, J. Bruno and S. Elad reported no relevant financial or non-financial interests to disclose within the last 3 years of beginning the work and none outside the 3-year time frame that could reasonably be perceived as influencing the submitted work. J.E. Raber-Durlacher was involved in a study funded by the Eklund Foundation for Odontological Research and Education. Y. Zadik received personal fees for lectures from S. Schestowitz and Taro Pharmaceutical Industries. J.B. Epstein is a consultant for Galera Therapeutics, Janssen Biopharmaceuticals, Nestle Healthcare, Tosk Inc. J.B. Epstein is a consultant and has funded research from SaNOtize Research and Development Corp. J.B. Epstein is associated Editor-in-Chief for Supportive Care in Cancer.
: The MASCC/ISOO OCSG Statements are developed to facilitate the expert-opinion based management of oral complications where high-quality evidence is lacking. Clinicians should use their judgment in making treatment decisions for individual patients. The Statement authors and the MASCC/ISOO do not guarantee or take responsibility for clinical outcomes in individual patients.